Tumor targeted NGS identified multiple somatic variants, specifically TP53 (c.586C>T, p.R196*, VAF 29%), SMARCB1 (c.215C>A, p.T72K, VAF 38%), and PTEN (c.203A>G, p.Y68C, VAF 8%). This evidence concerns the gene SMARCB1 and neoplasm.